Theravance Biopharma
TBPH
119 hedge funds and large institutions have $546M invested in Theravance Biopharma in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 49 reducing their positions, and 10 closing their positions.
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
44% more call options, than puts
Call options by funds: $431K | Put options by funds: $299K
5% more funds holding
Funds holding: 113 → 119 (+6)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4.37% less ownership
Funds ownership: 95.69% → 91.32% (-4.4%)
16% less capital invested
Capital invested by funds: $653M → $546M (-$106M)
41% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$4.28M |
| 2 |
Jane Street
New York
|
+$3.35M |
| 3 |
HF
HRT Financial
New York
|
+$3.32M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$3.31M |
| 5 |
SG Americas Securities
New York
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$33.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$14.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.28M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TWA
126
TCI Wealth Advisors
Tucson,
Arizona
| – | -$5.59K | -515 | Closed |
|
|
EI
127
Ellevest Inc
New York
| – | -$456 | -42 | Closed |
|
|
C
128
Covestor
London,
United Kingdom
| – | +$199 | +18 | New |
|
129
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$475 | +43 | New |
|
TBPH Hedge Fund Activity: Q2 2023 in Review
119 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2023, worth a combined $546M — down 16% from $653M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TBPH positions and 10 closed out — a net gain of 6 holders — while 29 added to existing stakes and 49 trimmed.
The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $4.28M. The largest seller was Baupost Group, cutting an estimated $33.1M.
- 119 institutional investors held Theravance Biopharma (TBPH) as of Q2 2023, up from 113 in Q1 2023.
- Funds reported $546M of Theravance Biopharma stock for Q2 2023, down 16% quarter-over-quarter.
- 16 funds opened new Theravance Biopharma positions in Q2 2023 and 10 closed out, a net change of +6 holders.
- The largest Theravance Biopharma buyer in Q2 2023 was Pictet Asset Management (Switzerland), an estimated $4.28M added.
- The largest Theravance Biopharma seller in Q2 2023 was Baupost Group, an estimated $33.1M sold.
Based on aggregated 13F filings for Q2 2023.